-
公开(公告)号:CA2863343A1
公开(公告)日:2013-07-25
申请号:CA2863343
申请日:2013-01-15
Applicant: VERTEX PHARMA
Inventor: HADIDA-RUAH SARA SABINA , ARUMUGAM VIJAYALAKSMI , DENINNO MICHAEL PAUL , FRIEMAN BRYAN A , KALLEL EDWARD ADAM , MILLER MARK THOMAS , UY JOHNNY , ZHOU JINGLAN
IPC: C07D491/107 , A61K31/438 , A61P25/00
Abstract: The invention relates to pyran spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
公开(公告)号:AU2012212196A1
公开(公告)日:2013-07-25
申请号:AU2012212196
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: HADIDA RUAH SARA S , KALLEL EDWARD ADAM , MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , MCCARTNEY JASON , ANDERSON COREY , GROOTENHUIS PETER DIEDERIK JAN , JIANG LICONG
IPC: C07D471/20 , A61K31/4985 , A61P25/00
Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
公开(公告)号:CA2812526A1
公开(公告)日:2011-11-10
申请号:CA2812526
申请日:2011-05-06
Applicant: VERTEX PHARMA
Inventor: HADIDA-RUAH SARA SABINA , KALLEL EDWARD ADAM , MILLER MARK THOMAS , PONTILLO JOSEPH , ANDERSON COREY , NUMA MEHDI , FRIEMAN BRYAN A , BEAR BRIAN RICHARD , ARUMUGAM VIJAYALAKSMI , HILGRAF NICOLE , MCCARTNEY JASON , GROOTENHUIS PETER DIEDERIK JAN , JOHNSON JAMES PHILIP
IPC: C07D491/20 , A61K31/438 , A61P25/04 , C07D498/20
Abstract: The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
公开(公告)号:HUE028983T2
公开(公告)日:2017-01-30
申请号:HUE11720264
申请日:2011-05-06
Applicant: VERTEX PHARMA
Inventor: HADIDA-RUAH SARA SABINA , KALLEL EDWARD ADAM , MILLER MARK THOMAS , PONTILLO JOSEPH , ANDERSON COREY , NUMA MEHDI , FRIEMAN BRYAN A , BEAR BRIAN RICHARD , ARUMUGAM VIJAYALAKSMI , HILGRAF NICOLE , MCCARTNEY JASON , GROOTENHUIS PETER DIEDERIK JAN , JOHNSON JAMES PHILIP
IPC: A61P25/04
-
公开(公告)号:SI2670752T1
公开(公告)日:2016-10-28
申请号:SI201230587
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: HADIDA RUAH SARA S , KALLEL EDWARD ADAM , MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , MCCARTNEY JASON , ANDERSON COREY , GROOTENHUIS PETER DIEDERIK JAN , JIANG LICONG
IPC: C07D471/00 , A61K31/00 , A61P25/00
-
公开(公告)号:AU2012212196B2
公开(公告)日:2016-10-13
申请号:AU2012212196
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: HADIDA RUAH SARA S , KALLEL EDWARD ADAM , MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , MCCARTNEY JASON , ANDERSON COREY , GROOTENHUIS PETER DIEDERIK JAN , JIANG LICONG
IPC: C07D471/20 , A61K31/4985 , A61P25/00
Abstract: The invention relates to pyrrolopyrazine-spirocyclic piperidine amide compounds useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
-
公开(公告)号:NZ615014A
公开(公告)日:2016-08-26
申请号:NZ61501412
申请日:2012-03-13
Applicant: VERTEX PHARMA
Inventor: KALLEL EDWARD ADAM , ARUMUGAM VIJAYALAKSMI , HILGRAF NICOLE , GROOTENHUIS PETER DIEDERIK JAN , MILLER MARK THOMAS , HADIDA-RUAH SARA SABINA , BINCH HAYLEY MARIE , DENINNO MICHAEL PAUL , FANNING LEV TYLER DEWEY , JOSHI PRAMOD , PONTILLO JOSEPH , SILINA ALINA , SHETH URVI JAGDISHBHAI , HURLEY DENNIS JAMES , FRIEMAN BRYAN A
IPC: C07D498/10 , A61K31/438 , A61K31/5386 , A61P29/00
Abstract: Disclosed are 1’-benzoyl-spiro[morpholine-2,4’-piperidine] derivatives and analogues as represented by the general formula (I) wherein the substituents are as defined herein. Representative compounds include 1’-(4-(3-hydroxypentan-3-yl)-3-methylbenzoyl)-4-(pyrimidin-2-yl)-6-ethyl-spiro[morpholine-2,4’-piperidine], 1’-(4-isopropoxy-3-methylbenzoyl)-4-(benzyl)-6-hydroxyethyl-spiro[morpholine-2,4’-piperidine], 1’-(4-(cyclopropyl(hydroxy)methyl)-benzoyl)-4-(2,2,2-trifluoroethyl)-6-phenyl-spiro[morpholine-2,4’-piperidine], 1’-(4-(isopropoxy)-3-methylbenzoyl)-4-(2-butyn-1-yl)-6-(2-fluoroethyl)-spiro[morpholine-2,4’-piperidine]. Also disclosed is a pharmaceutical composition comprising a compound as defined above and a pharmaceutically acceptable carrier, for inhibiting a voltage gated sodium ion channel, and for treating or lessening the severity of a condition selected from acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpatic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, and abnormal gastro-intestinal motility.
-
公开(公告)号:DK2670752T3
公开(公告)日:2016-07-04
申请号:DK12704985
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: KALLEL EDWARD ADAM , MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , MCCARTNEY JASON , ANDERSON COREY , GROOTENHUIS PETER DIEDERIK JAN , JIANG LICONG , HADIDA RUAH SARA S
IPC: C07D471/20 , A61K31/4985 , A61P25/00
-
公开(公告)号:ES2573497T3
公开(公告)日:2016-06-08
申请号:ES12704985
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: HADIDA RUAH SARA S , KALLEL EDWARD ADAM , MILLER MARK THOMAS , ARUMUGAM VIJAYALAKSMI , MCCARTNEY JASON , ANDERSON COREY , GROOTENHUIS PETER DIEDERIK JAN , JIANG LICONG
IPC: C07D471/20 , A61K31/4985 , A61P25/00
Abstract: Un compuesto de fórmula I:**Fórmula** o una sal farmacéuticamente aceptable de la misma, en donde, independientemente para cada aparición: R1 es H, C1-C8 alquilo, C3-C8 cicloalquilo, halo, CN, NR8SO2R8, SO2R8, SR8, SOR8, NR8COR8, NR8CO2R8, CON(R8)2, SO2N(R8)2, CF3, heterocicloalquilo, o un (C1-C8)-R9 de cadena lineal, ramificado o cíclico en donde hasta dos unidades CH2 pueden estar reemplazadas con O, CO, S, SO, SO2 o NR8, o dos R1 considerados juntos forman un grupo oxo, o un anillo cicloalquilo condensado de 3 a 7 miembros, o un anillo espirocíclico de 3 a 7 miembros; R2 es H, C1-C8 alquilo, halo, C1-C8 haloalquilo, CN, OH, SO2R8, SR8, SOR8, CO2R8, CON(R8)2, COR8, SO2N(R8)2, CF3, CHF2, o un (C1-C8)-R9 de cadena lineal, ramificado o cíclico en donde hasta dos unidades CH2 pueden estar reemplazadas con O, CO, S, SO, SO2, CF2, o NR8; R3 es H, C1-C8 alquilo, C3-C8 cicloalquilo, CO2R8, COR8, COH, CON(R8)2, CF3, CH2CF3, CH2CHF2, o un (C1-C8)-R9 de cadena lineal, ramificado o cíclico en donde hasta dos unidades CHF2 pueden estar reemplazadas con O, CO, S, SO, SO2, o NR8; R4 es H, C1-C8 alquilo, halo, C3-C8 cicloalquilo, en donde hasta dos unidades CH2 pueden estar reemplazadas por O, CO, S, SO, SO2, o NR8, o dos R4 considerados juntos forman un anillo cicloalquilo condensado de 3 a 7 miembros; R8 es H, C1-C8 alquilo, CF3, C3-C8 cicloalquilo, fluoroalquilo, arilo, heteroarilo, o un (C1-C8)-R9 de cadena lineal, ramificado o cíclico en donde hasta dos unidades CH2 pueden estar reemplazadas con O, CO, S, SO, SO2 o NR, o dos R8 considerados junto con los átomos a los que están unidos forman un anillo; R9 es H, CF3, CO2R, OH, arilo, heteroarilo, C3-C8 cicloalquilo, heterocicloalquilo, N(R)2, NRCOR, CON(R)2, CN, halo, o SO2R; R es H, C1-C8 alquilo, arilo, heteroarilo, C3-C8 cicloalquilo, o heterocicloalquilo; A es un arilo, heteroarilo o heterocíclico opcionalmente sustituido; m es un número entero de 0 a 4 inclusive; n es un número entero de 0 a 3 inclusive; y o es un número entero de 0 a 4 inclusive.
-
公开(公告)号:NZ613028A
公开(公告)日:2015-08-28
申请号:NZ61302812
申请日:2012-02-02
Applicant: VERTEX PHARMA
Inventor: KALLEL EDWARD ADAM , ANDERSON COREY , ARUMUGAM VIJAYALAKSMI , GROOTENHUIS PETER DIEDERIK JAN , HADIDA RUAH SARA S , MILLER MARK THOMAS , MCCARTNEY JASON , JIANG LICONG
IPC: C07D471/20 , A61K31/4985 , A61P25/00
Abstract: Disclosed are pyrrolopyrazine-spirocyclic piperidine amide compounds of formula (I) useful as inhibitors of ion channels. Also disclosed are pharmaceutically acceptable compositions comprising the compounds of formula (I) and methods of using the compositions in the treatment of various disorders. Examples of compounds of formula (I) are: 1-(1-(4-Isopropoxy-3-methoxybenzoyl)-6’-(trifluoromethyl)-3’,4’-dihydro-2’H-spiro[piperidine-4,1’-pyrrolo[1,2-a]pyrazine]-2’-yl)ethanone; 2,2,2-Trifluoro-1-[1’-[4-(2-methoxy-3-pyridyl)-3-methyl-benzoyl]-2-methyl-spiro[3,4-dihydropyrrolo [1,2-a] pyrazine-1,4’-piperidine]-6-yl] ethanone and (2-(3-Hydroxypyrrolidin-1-yl)pyridin-3-yl)(2’-methyl-6’-(trifluoromethyl)-3’,4’-dihydro-2’H-spiro[piperidine-4,1’-pyrrolo[1,2-a]pyrazine]-1-yl)methanone.
-
-
-
-
-
-
-
-
-